Clinical Trial Update: Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients [Phase 4]

View source ↗

Summary

Clinical trial NCT03146247 evaluating itch pathogenesis in response to apremilast in plaque psoriasis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Diamant Thaci | Conditions: Moderate to Severe Plaque Psoriasis | Phase 4 | Status: WITHDRAWN